Publications by authors named "Alan N Gordon"

Claim this Profile
I
Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy.
Neal S McCall, Tony Y Eng, Joseph W Shelton, Sheela Hanasoge, Pretesh R Patel, Alan N Gordon

Gynecol Oncol Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thirty-day Postoperative Adverse Events in Minimally Invasive versus Open Abdominal Radical Hysterectomy for Early-stage Cervical Cancer.
Adrian Y Kohut, Theresa Kuhn, Lesley B Conrad, Katherine Jane Chua, Madeline Abuelafiya, Alan N Gordon

J Minim Invasive Gynecol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Should a Gynecologist Know about Li-Fraumeni Syndrome? Lessons from a Patient Undergoing Hysterectomy for Benign Indications.
Polina Advolodkina, Mark P Lachiewicz, Gabriela Oprea-Ilies, Bhagirath Majmudar, Alan N Gordon

Gynecol Obstet Invest· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
Vinita M Alexander, Alan N Gordon, David H Howard, Namita Khanna

Int J Gynecol Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian carcinoma initially presenting as breast cancer two years prior to diagnosis: A case report and review of literature.
Lisa A Rauh, Mark P Lachiewicz, Alan N Gordon

Gynecol Oncol Rep· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Ignace Vergote, Russell J Schilder, Charles H Pippitt, Shirley Wong, Alan N Gordon

Gynecol Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Alan N Gordon, Michael Teneriello, Mike F Janicek, Jeffrey Hines, Peter C Lim

Gynecol Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Setsuko K Chambers, Mary C Clouser, Amanda F Baker, Denise J Roe, Haiyan Cui, Michael S Gordon, Alan N Gordon

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Radical abdominal trachelectomy for (microscopic) stage IB1 cervical cancer at 15-week gestation.
Alan N Gordon, Veronica L Schimp

Gynecol Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Howard A Burris, Chandra P Belani, Peter A Kaufman, Alan N Gordon, Lee S Schwartzberg

J Oncol Pract· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
Catherine Lhommé, Florence Joly, Joan L Walker, Andrea A Lissoni, Maria O Nicoletto, Alan N Gordon

J Clin Oncol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
David G Mutch, Mauro Orlando, Tiana Goss, Michael G Teneriello, Alan N Gordon

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Michael V Seiden, Alan N Gordon, Diane C Bodurka, Ursula A Matulonis, Richard T Penson

Gynecol Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of pegylated liposomal doxorubicin in ovarian cancer.
J Tate Thigpen, Carol A Aghajanian, David S Alberts, Susana M Campos, Alan N Gordon

Gynecol Oncol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of referral guidelines for women with pelvic masses.
Samuel S Im, Alan N Gordon, Barbara M Buttin, Charles A Leath, Bobbie S Gostout

Obstet Gynecol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal anthracycline treatment for ovarian cancer.
Maurie Markman, Alan N Gordon, William P McGuire, Franco M Muggia

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Alan N Gordon, Margaret Tonda, Steven Sun, Wayne Rackoff,

Gynecol Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Alan N Gordon, Birgit C Schultes, Holly Gallion, Robert Edwards, Theresa L Whiteside

Gynecol Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Alan N Gordon, Lina Asmar, Mark J Messing, Daron G Street, Charles H Pippitt

Gynecol Oncol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapeutic management of advanced ovarian cancer.
Alan N Gordon, Julie Butler

Semin Oncol Nurs· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma.
Stephen Y Chan, Alan N Gordon, Robert E Coleman, James B Hall, Mark S Berger

Cancer Immunol Immunother· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Alan N Gordon, Kenneth C Hancock, Carolyn M Matthews, Mark Messing, C A Stringer

Gynecol Oncol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis